[go: up one dir, main page]

MX2022000418A - Composicion farmaceutica de imatinib. - Google Patents

Composicion farmaceutica de imatinib.

Info

Publication number
MX2022000418A
MX2022000418A MX2022000418A MX2022000418A MX2022000418A MX 2022000418 A MX2022000418 A MX 2022000418A MX 2022000418 A MX2022000418 A MX 2022000418A MX 2022000418 A MX2022000418 A MX 2022000418A MX 2022000418 A MX2022000418 A MX 2022000418A
Authority
MX
Mexico
Prior art keywords
imatinib
pharmaceutical composition
pharmaceutically acceptable
present
composition
Prior art date
Application number
MX2022000418A
Other languages
English (en)
Inventor
Mayank Saxena
Venkataramana Naidu
Jwalant Vijaybhai Desai
Ashutosh Jamloki
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of MX2022000418A publication Critical patent/MX2022000418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende imatinib o una sal farmacéuticamente aceptable del mismo y uno o más excipientes farmacéuticamente aceptables en forma de polvo, que se puede reconstituir con un diluyente justo antes de la administración. Además, la presente invención proporciona un proceso para la preparación de la dicha composición y su uso para el tratamiento del cáncer en pacientes pediátricos.
MX2022000418A 2019-07-15 2020-07-15 Composicion farmaceutica de imatinib. MX2022000418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921028370 2019-07-15
PCT/IB2020/056641 WO2021009686A1 (en) 2019-07-15 2020-07-15 Pharmaceutical composition of imatinib

Publications (1)

Publication Number Publication Date
MX2022000418A true MX2022000418A (es) 2022-02-10

Family

ID=72145426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000418A MX2022000418A (es) 2019-07-15 2020-07-15 Composicion farmaceutica de imatinib.

Country Status (8)

Country Link
US (1) US20220265653A1 (es)
EP (1) EP3999027A1 (es)
AU (1) AU2020312840B2 (es)
BR (1) BR112022000571A2 (es)
CA (1) CA3145658A1 (es)
MX (1) MX2022000418A (es)
WO (1) WO2021009686A1 (es)
ZA (1) ZA202200330B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2008027600A2 (en) 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions
JP2010521477A (ja) 2007-03-12 2010-06-24 ドクター レディズ ラボラトリーズ リミテッド イマチニブメシレート
TR200802061A2 (tr) 2008-03-27 2009-07-21 Bi̇lgi̇ç Mahmut Yüksek oranda aktif madde içeren farmasötlk formülasyon.
PL394169A1 (pl) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2013008253A2 (en) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Imatinib formulations
BR112014012400A2 (pt) 2011-11-24 2017-06-13 Imuneks Farma Ilaç Sanayi Ve Ticaret A S formas de dosagens sólidas de imatinibe reconstituídas logo antes do uso
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
EP2749271A1 (en) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimized manufacturing method and pharmaceutical formulation of imatinib
EP3019159A4 (en) 2013-07-09 2017-01-18 Shilpa Medicare Limited Oral pharmaceutical compositions comprising imatinib mesylate
US10369078B2 (en) * 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
WO2019016673A2 (en) * 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
CN111278466A (zh) 2017-07-26 2020-06-12 夫特弗制药私人有限公司 伊马替尼的液体剂型

Also Published As

Publication number Publication date
CA3145658A1 (en) 2021-01-21
BR112022000571A2 (pt) 2022-03-15
EP3999027A1 (en) 2022-05-25
US20220265653A1 (en) 2022-08-25
AU2020312840B2 (en) 2026-01-22
WO2021009686A1 (en) 2021-01-21
AU2020312840A1 (en) 2022-01-20
ZA202200330B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MY187047A (en) Selective pyy compounds and uses thereof
CR20140086A (es) Tratamientos de combinación para hepatitis c
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018001989A (es) Formulaciones farmaceuticas.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2022000418A (es) Composicion farmaceutica de imatinib.
AR108792A1 (es) Composiciones que comprenden timolol
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
AR104427A1 (es) Composiciones farmacéuticas para terapia de combinación
MX2015009504A (es) Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina.
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos